Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
Sebastian Stintzing(Humboldt-Universität zu Berlin), Volker Heinemann(LMU Klinikum), Alexander Kiani(Bayreuth Medical Center), Sabine Tejpar(KU Leuven), Thomas Decker, Markus Moehler(Johannes Gutenberg University Mainz), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Dominik Paul Modest(Berliner Hochschule für Technik), Swantje Held(AIO Studien gGmbH), Dan Aderka(Sheba Medical Center), Pratyaksha Wirapati(SIB Swiss Institute of Bioinformatics), Andreas Jung(Ludwig-Maximilians-Universität München), Christoph Kahl(Klinikum Magdeburg), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Tobias Heintges(Lukaskrankenhaus), Florian Kaiser(University of Applied Sciences Landshut), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Werner Scheithauer(Comprehensive Cancer Center Vienna), G. Seipelt, Christian Lerchenmüller, Daniel Neureiter(Paracelsus Medical University), Frank Kullmann(Klinikum Weiden), Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 194
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.2k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k